Govt Orders Recall as Natco Cancer Drug Fails Toxin Test

Summary posted by Meridian on 7/24/2009
Source: Trading Markets
Author: n/a

The government of India has ordered the Hyderbad, India, based company Natco Pharma, to recall its breast cancer drug Albupax from the market within two weeks. Tests showed that the drug, a nanotechnology-based generic version of a drug by the United States company Abraxis, could cause damage to the liver. A Natco spokesperson confirmed that the company had suspended production of the the drug, but sought to defend it by saying that testing procedures for nanotechnology-based products are complex. A government official said that "Abraxis had collected samples of Albupax and got them tested in several labs in the US. Its complaint to the Indian regulator was based on those studies of the collected samples. Natco Pharma has also been asked to stop production of Albupax till investigations are over." The Drug Controller General of India (DCGI) said that Albupax failed endotoxin tests. Drug complications can cause serious problems for breast cancer patients who are also undergoing surgery, radiotherapy and chemotherapy. The article can be viewed online at the link below.

As tagged by Meridian Institute:

Related Forums:

NDN Home

Manage Subscription

Search News Archives

Understanding Public Debate on Nanotechnologies: Options for Framing Public Policy -- The Innovation Society (2/8/2010) The Governance and Ethics Unit of the Directorate General for Research (DG Research) of the European Commission (EC) has published an overview paper on options for framing public policy on nanotechnologies. [More]

UN Patent Filings Dropped for 1st Time Since 1978 -- ABC news (2/8/2010) The United Nations World Intellectual Property Organization (WIPO), an entity through which a company can, for a fee, file a request for patent protection in any or all of the 142 countries that have subscribed to the U.N.'s Patent Cooperation Treaty, reported that the number of international patent filings dropped last year for the first time since 1978. [More]

TECHNOLOGY: Science Panel Probes Renewable Energy's Current Use of China's Rare Metals -- Environment & Energy Daily (2/8/2010) A United States House of Representatives Science and Technology subcommittee this week will hold a hearing on rare earth mineral production and the resource's role in the growing clean energy industry. [More]

Nanofood for Thought -- Nature Nanotechnology (2/5/2010) This editorial, in the journal Nature Nanotechnology, is in response to the recent report, "Nanotechnologies and Food", released in January by the House of Lords Science and Technology Committee, United Kingdom, that criticized the food industry for failing to be transparent about its research into the uses of nanotechnologies and nanomaterials. [More]

More News...

Learn how to include these headlines on your own website by clicking here.

Please email us if you require text-only versions of the daily emails.








our team contact us site map	Govt Orders Recall as Natco Cancer Drug Fails Toxin Test Summary posted by Meridian on 7/24/2009 Source: Trading Markets Author: n/a The government of India has ordered the Hyderbad, India, based company Natco Pharma, to recall its breast cancer drug Albupax from the market within two weeks. Tests showed that the drug, a nanotechnology-based generic version of a drug by the United States company Abraxis, could cause damage to the liver. A Natco spokesperson confirmed that the company had suspended production of the the drug, but sought to defend it by saying that testing procedures for nanotechnology-based products are complex. A government official said that "Abraxis had collected samples of Albupax and got them tested in several labs in the US. Its complaint to the Indian regulator was based on those studies of the collected samples. Natco Pharma has also been asked to stop production of Albupax till investigations are over." The Drug Controller General of India (DCGI) said that Albupax failed endotoxin tests. Drug complications can cause serious problems for breast cancer patients who are also undergoing surgery, radiotherapy and chemotherapy. The article can be viewed online at the link below. The original article may still be available at www.tradingmarkets.com/.site/news/Stock%20News/2438786/ As tagged by Meridian Institute: Health And Medical: Diseases Implications: Human Enhancement, Human Health Risks, Governance, Economic Competitiveness Materials And Manufacturing: Manufacturing Nanomaterials: Naturally Occurring Regions: North America, East and South Asia and the Pacific Stakeholders: Government, Industry Related Forums: Health and Medical Materials and Manufacturing Human Health Risks and Worker Safety Economic Competitiveness Governance print format	NDN Home Subscribe Manage Subscription Search News Archives Understanding Public Debate on Nanotechnologies: Options for Framing Public Policy -- The Innovation Society (2/8/2010) The Governance and Ethics Unit of the Directorate General for Research (DG Research) of the European Commission (EC) has published an overview paper on options for framing public policy on nanotechnologies. [More] UN Patent Filings Dropped for 1st Time Since 1978 -- ABC news (2/8/2010) The United Nations World Intellectual Property Organization (WIPO), an entity through which a company can, for a fee, file a request for patent protection in any or all of the 142 countries that have subscribed to the U.N.'s Patent Cooperation Treaty, reported that the number of international patent filings dropped last year for the first time since 1978. [More] TECHNOLOGY: Science Panel Probes Renewable Energy's Current Use of China's Rare Metals -- Environment & Energy Daily (2/8/2010) A United States House of Representatives Science and Technology subcommittee this week will hold a hearing on rare earth mineral production and the resource's role in the growing clean energy industry. [More] Nanofood for Thought -- Nature Nanotechnology (2/5/2010) This editorial, in the journal Nature Nanotechnology, is in response to the recent report, "Nanotechnologies and Food", released in January by the House of Lords Science and Technology Committee, United Kingdom, that criticized the food industry for failing to be transparent about its research into the uses of nanotechnologies and nanomaterials. [More] More News... Learn how to include these headlines on your own website by clicking here. Please email us if you require text-only versions of the daily emails.